{"DataElement":{"publicId":"6951325","version":"1","preferredName":"Intervention or Procedure Plan Type","preferredDefinition":"A response used to determine the planned activity to be used that produces an effect, or is intended to alter the course of a disease in a patient or population.","longName":"6951315v1.0:6161027v1.0","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"6951315","version":"1","preferredName":"Intervention or Procedure Plan","preferredDefinition":"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects._To devise, contrive, or form in design.","longName":"2233215v1.0:2475238v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"2233215","version":"1","preferredName":"Procedure","preferredDefinition":"A particular course of action intended to achieve a result.","longName":"C25218","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intervention or Procedure","conceptCode":"C25218","definition":"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9313AE8-B7EE-4260-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-12","modifiedBy":"ONEDATA","dateModified":"2005-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2475238","version":"1","preferredName":"Planned","preferredDefinition":"Planned; devised, contrived, or formed in design.","longName":"C25619","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plan","conceptCode":"C25619","definition":"To devise, contrive, or form in design.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11A2D427-7660-5E1B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-17","modifiedBy":"ONEDATA","dateModified":"2006-04-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"93C799E4-682E-4B6A-E053-F662850AC574","latestVersionIndicator":"Yes","beginDate":"2019-09-30","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-09-30","modifiedBy":"GARRIDOJ","dateModified":"2021-03-08","changeDescription":"Created for EA5181, 09/30/2019 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6161027","version":"1","preferredName":"Treatment Regimen Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6161027v1.0","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Arm T: Registration to Standard Chemo/XRT","valueDescription":"Protocol Treatment Arm Registration To Standard Chemoradiotherapy","ValueMeaning":{"publicId":"6161028","version":"1","preferredName":"Protocol Treatment Arm Registration To Standard Chemoradiotherapy","longName":"6161028","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: The act of listing or recording officially; officially qualified or enrolled.: Used as a function word to indicate direction, purpose, or movement.: Regularly and widely used.: Treatment that combines chemotherapy with radiation therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Registration","conceptCode":"C25646","definition":"The act of listing or recording officially; officially qualified or enrolled.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Standard","conceptCode":"C44275","definition":"Regularly and widely used.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemoradiotherapy","conceptCode":"C94626","definition":"Treatment that combines chemotherapy with radiation therapy. Chemoradiation can be concurrent or sequential. ","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6906371E-11D7-4BF1-E053-F662850AF52D","latestVersionIndicator":"Yes","beginDate":"2018-04-04","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-04-04","modifiedBy":"ONEDATA","dateModified":"2018-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6906371E-11F2-4BF1-E053-F662850AF52D","beginDate":"2018-04-04","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-04-04","modifiedBy":"ONEDATA","dateModified":"2018-04-04","deletedIndicator":"No"},{"value":"Arm S: Registration following Standard Chemo/XRT","valueDescription":"Protocol Treatment Arm Registration Post Standard Chemoradiotherapy","ValueMeaning":{"publicId":"6161029","version":"1","preferredName":"Protocol Treatment Arm Registration Post Standard Chemoradiotherapy","longName":"6161029","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: The act of listing or recording officially; officially qualified or enrolled.: Happening at a time subsequent to a reference time; later in time or order.: Regularly and widely used.: Treatment that combines chemotherapy with radiation therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Registration","conceptCode":"C25646","definition":"The act of listing or recording officially; officially qualified or enrolled.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Standard","conceptCode":"C44275","definition":"Regularly and widely used.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemoradiotherapy","conceptCode":"C94626","definition":"Treatment that combines chemotherapy with radiation therapy. Chemoradiation can be concurrent or sequential. ","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6906371E-1202-4BF1-E053-F662850AF52D","latestVersionIndicator":"Yes","beginDate":"2018-04-04","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-04-04","modifiedBy":"ONEDATA","dateModified":"2018-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6906371E-121D-4BF1-E053-F662850AF52D","beginDate":"2018-04-04","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-04-04","modifiedBy":"ONEDATA","dateModified":"2018-04-04","deletedIndicator":"No"},{"value":"Arm O: Histology confirmation not required","valueDescription":"Protocol Treatment Arm Histology Confirmation Negation Requirement","ValueMeaning":{"publicId":"6471206","version":"1","preferredName":"Protocol Treatment Arm Histology Confirmation Negation Requirement","longName":"6471206","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.: Having been established or verified.: An operation in which a term denies or inverts the meaning of another term or construction.: Something that is a necessary condition; something that is obligatory.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Histology","conceptCode":"C16681","definition":"The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Requirement","conceptCode":"C25652","definition":"Something that is a necessary condition; something that is obligatory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77BAEA5B-9DF6-7D02-E053-F662850AE953","latestVersionIndicator":"Yes","beginDate":"2018-10-08","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-10-08","modifiedBy":"ONEDATA","dateModified":"2018-10-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77BAEA5B-9E11-7D02-E053-F662850AE953","beginDate":"2018-10-08","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-10-08","modifiedBy":"ONEDATA","dateModified":"2018-10-08","deletedIndicator":"No"},{"value":"Arm H: Histology confirmation required","valueDescription":"Protocol Treatment Arm Histology Confirmation Requirement","ValueMeaning":{"publicId":"6471207","version":"1","preferredName":"Protocol Treatment Arm Histology Confirmation Requirement","longName":"6471207","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.: Having been established or verified.: Something that is a necessary condition; something that is obligatory.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Histology","conceptCode":"C16681","definition":"The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Requirement","conceptCode":"C25652","definition":"Something that is a necessary condition; something that is obligatory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77BAEA5B-9E20-7D02-E053-F662850AE953","latestVersionIndicator":"Yes","beginDate":"2018-10-08","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-10-08","modifiedBy":"ONEDATA","dateModified":"2018-10-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77BAEA5B-9E3B-7D02-E053-F662850AE953","beginDate":"2018-10-08","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-10-08","modifiedBy":"ONEDATA","dateModified":"2018-10-08","deletedIndicator":"No"},{"value":"Arm A: Carboplatin, Paclitaxel and RT","valueDescription":"Protocol Treatment Arm Carboplatin Paclitaxel And Radiation Therapy","ValueMeaning":{"publicId":"6429364","version":"1","preferredName":"Protocol Treatment Arm Carboplatin Paclitaxel And Radiation Therapy","longName":"6429364","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"759DC36D-79C9-5D4D-E053-F662850AD468","latestVersionIndicator":"Yes","beginDate":"2018-09-11","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"759DC36D-79E4-5D4D-E053-F662850AD468","beginDate":"2018-09-11","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","deletedIndicator":"No"},{"value":"Arm B: Carboplatin, Paclitaxel, Nivolumab and RT","valueDescription":"Protocol Treatment Arm Carboplatin Paclitaxel Nivolumab And Radiation Therapy","ValueMeaning":{"publicId":"6429365","version":"1","preferredName":"Protocol Treatment Arm Carboplatin Paclitaxel Nivolumab And Radiation Therapy","longName":"6429365","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04): A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.: An article which expresses the relation of connection or addition. It ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"759DC36D-79F5-5D4D-E053-F662850AD468","latestVersionIndicator":"Yes","beginDate":"2018-09-11","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"759DC36D-7A10-5D4D-E053-F662850AD468","beginDate":"2018-09-11","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","deletedIndicator":"No"},{"value":"Arm A: Paclitaxel 80 mg/m2 every 7 days for 4 cycles","valueDescription":"Protocol Treatment Arm Paclitaxel Eighty Milligram per Square Meter Every Seven Days For Four Cycle","ValueMeaning":{"publicId":"6757197","version":"1","preferredName":"Protocol Treatment Arm Paclitaxel Eighty Milligram per Square Meter Every Seven Days For Four Cycle","longName":"6757197","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04): A natural number greater than seventy-nine and less than eighty-one and the quantity that it denotes.: A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.: Every seven days.: The reason of something.: A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.: An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Eighty","conceptCode":"C105788","definition":"A natural number greater than seventy-nine and less than eighty-one and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Milligram per Square Meter","conceptCode":"C67402","definition":"A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Every Seven Days","conceptCode":"C139177","definition":"Every seven days.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"For","conceptCode":"C64956","definition":"The reason of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Four","conceptCode":"C66835","definition":"A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cycle","conceptCode":"C25472","definition":"An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"88F072FD-3133-45CF-E053-F662850AED7F","latestVersionIndicator":"Yes","beginDate":"2019-05-15","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-05-15","modifiedBy":"ONEDATA","dateModified":"2019-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"88F072FD-314E-45CF-E053-F662850AED7F","beginDate":"2019-05-15","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-05-15","modifiedBy":"ONEDATA","dateModified":"2019-05-15","deletedIndicator":"No"},{"value":"Arm B: Docetaxel 75 mg/m2 every 3 weeks for 4 cycles","valueDescription":"Protocol Treatment Arm Docetaxel Seventy Five Milligram per Square Meter Every Three Weeks For Four Cycle","ValueMeaning":{"publicId":"6759284","version":"1","preferredName":"Protocol Treatment Arm Docetaxel Seventy Five Milligram per Square Meter Every Three Weeks For Four Cycle","longName":"6759284","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04): A natural number greater than seventy-four and less than seventy-six and the quantity that it denotes.: A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.: Every three weeks.: The reason of something.: A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.: An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Seventy Five","conceptCode":"C160687","definition":"A natural number greater than seventy-four and less than seventy-six and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Milligram per Square Meter","conceptCode":"C67402","definition":"A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Every Three Weeks","conceptCode":"C64535","definition":"Every three weeks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"For","conceptCode":"C64956","definition":"The reason of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Four","conceptCode":"C66835","definition":"A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cycle","conceptCode":"C25472","definition":"An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89030B40-9C9C-41B3-E053-F662850A27BE","latestVersionIndicator":"Yes","beginDate":"2019-05-16","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-05-16","modifiedBy":"ONEDATA","dateModified":"2019-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89030B40-9CB7-41B3-E053-F662850A27BE","beginDate":"2019-05-16","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-05-16","modifiedBy":"ONEDATA","dateModified":"2019-05-16","deletedIndicator":"No"},{"value":"Arm B - Carboplatin, Paclitaxel, Nivolumab and RT","valueDescription":"Protocol Treatment Arm Carboplatin Paclitaxel Nivolumab Radiation Therapy","ValueMeaning":{"publicId":"7155637","version":"1","preferredName":"Protocol Treatment Arm Carboplatin Paclitaxel Nivolumab Radiation Therapy","longName":"7155637","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04): A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.: Treatment of a","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D4F3977-1057-5431-E053-F662850AB7E2","latestVersionIndicator":"Yes","beginDate":"2020-01-29","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-01-29","modifiedBy":"ONEDATA","dateModified":"2020-01-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D4F3977-1070-5431-E053-F662850AB7E2","beginDate":"2020-01-29","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-01-29","modifiedBy":"ONEDATA","dateModified":"2020-01-29","deletedIndicator":"No"},{"value":"Arm A - Carboplatin, Paclitaxel and RT","valueDescription":"Protocol Treatment Arm Carboplatin Paclitaxel Radiation Therapy","ValueMeaning":{"publicId":"7155638","version":"1","preferredName":"Protocol Treatment Arm Carboplatin Paclitaxel Radiation Therapy","longName":"7155638","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04): Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D4F3977-107F-5431-E053-F662850AB7E2","latestVersionIndicator":"Yes","beginDate":"2020-01-29","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-01-29","modifiedBy":"ONEDATA","dateModified":"2020-01-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D4F3977-1098-5431-E053-F662850AB7E2","beginDate":"2020-01-29","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-01-29","modifiedBy":"ONEDATA","dateModified":"2020-01-29","deletedIndicator":"No"},{"value":"Carboplatin-Paclitaxel","valueDescription":"Carboplatin-Paclitaxel Regimen","ValueMeaning":{"publicId":"6951324","version":"1","preferredName":"Carboplatin-Paclitaxel Regimen","longName":"6951324","preferredDefinition":"A regimen consisting of carboplatin and paclitaxel that may be used for the treatment of endometrial, ovarian, head and neck, and advanced-stage non-small cell lung cancer (NSCLC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin/Paclitaxel Regimen","conceptCode":"C63402","definition":"A regimen consisting of carboplatin and paclitaxel that may be used for the treatment of breast, kidney, cervical, vulvar, endometrial, ovarian, fallopian tube, primary peritoneal, head and neck, and advanced-stage non-small cell lung cancer (NSCLC); anal, small bowel, anaplastic and certain bladder adenocarcinomas; salivary gland, malignant germ cell and malignant sex cord-stromal tumors;  cutaneous and uveal melanoma; thymomas and thymic carcinoma; occult primary adenocarcinoma or squamous cell carcinoma. Paclitaxel/carboplatin every 21 days regimen may be used for the treatment of esophageal and esophagogastric junction, and gastric cancers. Paclitaxel plus intraperitoneal (IP) carboplatin plus IP paclitaxel regimen can be used in the treatment of ovarian, fallopian tube, and primary peritoneal cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93C7BA40-135C-2259-E053-F662850AF0FD","latestVersionIndicator":"Yes","beginDate":"2019-09-30","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-09-30","modifiedBy":"ONEDATA","dateModified":"2019-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93C7BA40-1377-2259-E053-F662850AF0FD","beginDate":"2019-09-30","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-09-30","modifiedBy":"ONEDATA","dateModified":"2019-09-30","deletedIndicator":"No"},{"value":"Cisplatin-Pemetrexed","valueDescription":"Pemetrexed-Cisplatin Regimen","ValueMeaning":{"publicId":"3557952","version":"1","preferredName":"Pemetrexed-Cisplatin Regimen","longName":"3557952","preferredDefinition":"A regimen consisting of pemetrexed and cisplatin used for the treatment of malignant mesothelioma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Pemetrexed Regimen","conceptCode":"C63788","definition":"A regimen consisting of pemetrexed and cisplatin that may be used for the treatment of malignant peritoneal and pleural mesothelioma, and non-small cell lung cancer (NSCLC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7502A41-7F0F-66C6-E040-BB89AD43459A","latestVersionIndicator":"Yes","beginDate":"2012-08-15","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-08-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93C7BA40-138C-2259-E053-F662850AF0FD","beginDate":"2019-09-30","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-09-30","modifiedBy":"ONEDATA","dateModified":"2019-09-30","deletedIndicator":"No"},{"value":"Cisplatin-Etoposide","valueDescription":"Cisplatin Etoposide Treatment Regimen","ValueMeaning":{"publicId":"3378874","version":"1","preferredName":"Cisplatin Etoposide Treatment Regimen","longName":"3378874","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-3F30-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93C7BA40-13A3-2259-E053-F662850AF0FD","beginDate":"2019-09-30","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-09-30","modifiedBy":"ONEDATA","dateModified":"2019-09-30","deletedIndicator":"No"},{"value":"Arm A: FOLFOX","valueDescription":"Protocol Treatment Arm FOLFOX Regimen","ValueMeaning":{"publicId":"6975974","version":"1","preferredName":"Protocol Treatment Arm FOLFOX Regimen","longName":"6975974","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: One of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"FOLFOX Regimen","conceptCode":"C11197","definition":"One of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9491DF63-4B06-12FE-E053-F662850A8791","latestVersionIndicator":"Yes","beginDate":"2019-10-10","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-10-10","modifiedBy":"ONEDATA","dateModified":"2019-10-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9491DF63-4B21-12FE-E053-F662850A8791","beginDate":"2019-10-10","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-10-10","modifiedBy":"ONEDATA","dateModified":"2019-10-10","deletedIndicator":"No"},{"value":"Arm B: CAPOX","valueDescription":"Protocol Treatment Arm CAPOX Regimen","ValueMeaning":{"publicId":"6975975","version":"1","preferredName":"Protocol Treatment Arm CAPOX Regimen","longName":"6975975","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A regimen consisting of capecitabine and oxaliplatin used as a treatment for advanced stage colorectal cancer. This regimen differs from a similar regimen, XELOX, with regards to the dosing schedule for oxaliplatin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"CAPOX Regimen","conceptCode":"C63596","definition":"A regimen consisting of capecitabine and oxaliplatin that can be used for the treatment of ampullary, appendiceal, pancreatic and small bowel adenocarcinomas, colorectal, gastric, esophageal and esophagogastric junction cancers, certain neuroendocrine tumors, occult primary tumors and mucinous carcinoma of the ovary. Low-dose CapeOX may be used for the treatment of gastric, esophageal and esophagogastric junction cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9491DF63-4B2E-12FE-E053-F662850A8791","latestVersionIndicator":"Yes","beginDate":"2019-10-10","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-10-10","modifiedBy":"ONEDATA","dateModified":"2019-10-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9491DF63-4B49-12FE-E053-F662850A8791","beginDate":"2019-10-10","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-10-10","modifiedBy":"ONEDATA","dateModified":"2019-10-10","deletedIndicator":"No"},{"value":"Arm B: Docetaxel 75 mg/m2 every 3 weeks for 4-6 cycles","valueDescription":"Protocol Treatment Arm Docetaxel Seventy Five Milligram per Square Meter Every Three Weeks For Four To Six Cycle","ValueMeaning":{"publicId":"7252808","version":"1","preferredName":"Protocol Treatment Arm Docetaxel Seventy Five Milligram per Square Meter Every Three Weeks For Four To Six Cycle","longName":"7252808","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04): A natural number greater than seventy-four and less than seventy-six and the quantity that it denotes.: A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.: Every three weeks.: The reason of something.: A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.: Used as a function word to indicate direction, purpose, or movement.: A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.: An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Seventy Five","conceptCode":"C160687","definition":"A natural number greater than seventy-four and less than seventy-six and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Milligram per Square Meter","conceptCode":"C67402","definition":"A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Every Three Weeks","conceptCode":"C64535","definition":"Every three weeks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"For","conceptCode":"C64956","definition":"The reason of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Four","conceptCode":"C66835","definition":"A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Six","conceptCode":"C66837","definition":"A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cycle","conceptCode":"C25472","definition":"An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3BD5EAD-3621-7F90-E053-F662850AA2D3","latestVersionIndicator":"Yes","beginDate":"2020-04-20","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-04-20","modifiedBy":"ONEDATA","dateModified":"2020-04-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3BCF4A2-54DF-59AC-E053-F662850A0C55","beginDate":"2020-04-20","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-04-20","modifiedBy":"ONEDATA","dateModified":"2020-04-20","deletedIndicator":"No"},{"value":"Ramucirumab plus docetaxel","valueDescription":"Docetaxel/Ramucirumab Regimen","ValueMeaning":{"publicId":"7263275","version":"1","preferredName":"Docetaxel/Ramucirumab Regimen","longName":"7263275","preferredDefinition":"A chemoimmunotherapy regimen consisting of ramucirumab and docetaxel that is used for the treatment of non-small cell lung cancer (NSCLC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel/Ramucirumab Regimen","conceptCode":"C136285","definition":"A regimen consisting of ramucirumab and docetaxel that is used for the treatment of non-small cell lung cancer (NSCLC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4475F36-A4FD-4224-E053-F662850A3361","latestVersionIndicator":"Yes","beginDate":"2020-04-27","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-04-27","modifiedBy":"ONEDATA","dateModified":"2020-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A4475F36-A518-4224-E053-F662850A3361","beginDate":"2020-04-27","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-04-27","modifiedBy":"ONEDATA","dateModified":"2020-04-27","deletedIndicator":"No"},{"value":"Other single agent chemotherapy without ramucirumab","valueDescription":"Other Single Agent Chemotherapy Without Ramucirumab","ValueMeaning":{"publicId":"7263276","version":"1","preferredName":"Other Single Agent Chemotherapy Without Ramucirumab","longName":"7263276","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Not accompanied by another or others; exclusive of anyone or anything else.: An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.: The use of synthetic or naturally-occurring chemicals for the treatment of diseases.: Used to indicate the absence or lack of something or someone.: A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Single","conceptCode":"C48440","definition":"Not accompanied by another or others; exclusive of anyone or anything else.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Ramucirumab","conceptCode":"C70792","definition":"A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4475F36-A529-4224-E053-F662850A3361","latestVersionIndicator":"Yes","beginDate":"2020-04-27","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-04-27","modifiedBy":"ONEDATA","dateModified":"2020-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A4475F36-A544-4224-E053-F662850A3361","beginDate":"2020-04-27","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-04-27","modifiedBy":"ONEDATA","dateModified":"2020-04-27","deletedIndicator":"No"},{"value":"Modified Hyper-CVAD protocol","valueDescription":"Change HyperCVAD Regimen Protocol","ValueMeaning":{"publicId":"7426136","version":"1","preferredName":"Change HyperCVAD Regimen Protocol","longName":"7426136","preferredDefinition":"The act of alteration or modification; changed or altered in form or character.: A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule that is used to treat adult acute lymphoblastic leukemia (ALL) or Burkitt-type ALL and adult small non-cleaved cell (Burkitt) lymphoma.: A rule which guides how an activity should be performed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Change","conceptCode":"C25446","definition":"The act of alteration or modification; changed or altered in form or character.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"HyperCVAD Regimen","conceptCode":"C63455","definition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule that is used to treat adult acute lymphoblastic leukemia (ALL) or Burkitt-type ALL and adult small non-cleaved cell (Burkitt) lymphoma, AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN) and T-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Protocol","conceptCode":"C42651","definition":"A rule which guides how an activity should be performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF9BF2D6-CAD9-51D0-E053-4EBD850A91F8","latestVersionIndicator":"Yes","beginDate":"2020-09-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-09-18","modifiedBy":"ONEDATA","dateModified":"2020-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF9BF2D6-CAF4-51D0-E053-4EBD850A91F8","beginDate":"2020-09-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-09-18","modifiedBy":"ONEDATA","dateModified":"2020-09-18","deletedIndicator":"No"},{"value":"Full Hyper-CVAD protocol","valueDescription":"Full HyperCVAD Regimen Protocol","ValueMeaning":{"publicId":"7426137","version":"1","preferredName":"Full HyperCVAD Regimen Protocol","longName":"7426137","preferredDefinition":"Containing as much or as many as is possible or normal.: A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule that is used to treat adult acute lymphoblastic leukemia (ALL) or Burkitt-type ALL and adult small non-cleaved cell (Burkitt) lymphoma.: A rule which guides how an activity should be performed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Full","conceptCode":"C25517","definition":"Containing as much or as many as is possible or normal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"HyperCVAD Regimen","conceptCode":"C63455","definition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule that is used to treat adult acute lymphoblastic leukemia (ALL) or Burkitt-type ALL and adult small non-cleaved cell (Burkitt) lymphoma, AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN) and T-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Protocol","conceptCode":"C42651","definition":"A rule which guides how an activity should be performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF9BF2D6-CB02-51D0-E053-4EBD850A91F8","latestVersionIndicator":"Yes","beginDate":"2020-09-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-09-18","modifiedBy":"ONEDATA","dateModified":"2020-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF9BF2D6-CB1D-51D0-E053-4EBD850A91F8","beginDate":"2020-09-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-09-18","modifiedBy":"ONEDATA","dateModified":"2020-09-18","deletedIndicator":"No"},{"value":"N/A - patient greater than or equal to 70 years of age","valueDescription":"Not Applicable Patient Greater Than or Equal To Seventy Year Age","ValueMeaning":{"publicId":"7426138","version":"1","preferredName":"Not Applicable Patient Greater Than or Equal To Seventy Year Age","longName":"7426138","preferredDefinition":"Determination of a value is not relevant in the current context.: A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways.: A natural number greater than sixty-nine and less than seventy-one and the quantity that it denotes.: A period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period.: How long something has existed; elapsed time since birth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Greater Than or Equal To","conceptCode":"C61583","definition":"A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Seventy","conceptCode":"C105790","definition":"A natural number greater than sixty-nine and less than seventy-one and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Year","conceptCode":"C29848","definition":"A period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Age","conceptCode":"C25150","definition":"How long something has existed; elapsed time since birth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF9BF2D6-CB2E-51D0-E053-4EBD850A91F8","latestVersionIndicator":"Yes","beginDate":"2020-09-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-09-18","modifiedBy":"ONEDATA","dateModified":"2020-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF9BF2D6-CB49-51D0-E053-4EBD850A91F8","beginDate":"2020-09-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-09-18","modifiedBy":"ONEDATA","dateModified":"2020-09-18","deletedIndicator":"No"},{"value":"N/A - patient greater than 70 years of age","valueDescription":"Not Applicable Patient Greater Than Seventy Year Age","ValueMeaning":{"publicId":"7426139","version":"1","preferredName":"Not Applicable Patient Greater Than Seventy Year Age","longName":"7426139","preferredDefinition":"Determination of a value is not relevant in the current context.: A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.: A natural number greater than sixty-nine and less than seventy-one and the quantity that it denotes.: A period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period.: How long something has existed; elapsed time since birth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Greater Than","conceptCode":"C61584","definition":"A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Seventy","conceptCode":"C105790","definition":"A natural number greater than sixty-nine and less than seventy-one and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Year","conceptCode":"C29848","definition":"A period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Age","conceptCode":"C25150","definition":"How long something has existed; elapsed time since birth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF9BF2D6-CB5A-51D0-E053-4EBD850A91F8","latestVersionIndicator":"Yes","beginDate":"2020-09-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-09-18","modifiedBy":"ONEDATA","dateModified":"2020-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF9BF2D6-CB75-51D0-E053-4EBD850A91F8","beginDate":"2020-09-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-09-18","modifiedBy":"ONEDATA","dateModified":"2020-09-18","deletedIndicator":"No"},{"value":"Other single agent chemotherapy without ramucirumab but with docetaxel, gemcitabine, paclitaxel or nab-paclitaxel","valueDescription":"Other Single Agent Chemotherapy Without Ramucirumab With Docetaxel Gemcitabine Paclitaxel Or Nab-paclitaxel","ValueMeaning":{"publicId":"7631795","version":"1","preferredName":"Other Single Agent Chemotherapy Without Ramucirumab With Docetaxel Gemcitabine Paclitaxel Or Nab-paclitaxel","longName":"7631795","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Not accompanied by another or others; exclusive of anyone or anything else.: An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.: The use of synthetic or naturally-occurring chemicals for the treatment of diseases.: Used to indicate the absence or lack of something or someone.: A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.: Used to indicate the presence of something or someone.: A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04): A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribo","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"11"},{"longName":"Single","conceptCode":"C48440","definition":"Not accompanied by another or others; exclusive of anyone or anything else.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"10"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Ramucirumab","conceptCode":"C70792","definition":"A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Nab-paclitaxel","conceptCode":"C2688","definition":"A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFCB167E-AB7E-5815-E053-4EBD850A82B5","latestVersionIndicator":"Yes","beginDate":"2021-04-12","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-04-12","modifiedBy":"ONEDATA","dateModified":"2021-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BFCB167E-AB99-5815-E053-4EBD850A82B5","beginDate":"2021-04-12","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-04-12","modifiedBy":"ONEDATA","dateModified":"2021-04-12","deletedIndicator":"No"},{"value":"Arm B: Cisplatin + RT followed by Observation","valueDescription":"Protocol Treatment Arm Cisplatin And Radiation Therapy Next Observation","ValueMeaning":{"publicId":"7552172","version":"1","preferredName":"Protocol Treatment Arm Cisplatin And Radiation Therapy Next Observation","longName":"7552172","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.: Subsequent; immediately following in time or order.: Watching something and taking note of what happens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Next","conceptCode":"C53286","definition":"Subsequent; immediately following in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Observation","conceptCode":"C25598","definition":"Watching something and taking note of what happens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B96E103A-AE12-42E8-E053-4EBD850A77C6","latestVersionIndicator":"Yes","beginDate":"2021-01-21","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-01-21","modifiedBy":"ONEDATA","dateModified":"2021-01-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B96E103A-AE2D-42E8-E053-4EBD850A77C6","beginDate":"2021-01-21","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-01-21","modifiedBy":"ONEDATA","dateModified":"2021-01-21","deletedIndicator":"No"},{"value":"Arm A: Cisplatin + RT followed by Nivolumab","valueDescription":"Protocol Treatment Arm Cisplatin And Radiation Therapy Next Nivolumab","ValueMeaning":{"publicId":"7552173","version":"1","preferredName":"Protocol Treatment Arm Cisplatin And Radiation Therapy Next Nivolumab","longName":"7552173","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.: Subsequent; immediately following in time or order.: A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Next","conceptCode":"C53286","definition":"Subsequent; immediately following in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B96E103A-AE3E-42E8-E053-4EBD850A77C6","latestVersionIndicator":"Yes","beginDate":"2021-01-21","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-01-21","modifiedBy":"ONEDATA","dateModified":"2021-01-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B96E103A-AE59-42E8-E053-4EBD850A77C6","beginDate":"2021-01-21","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-01-21","modifiedBy":"ONEDATA","dateModified":"2021-01-21","deletedIndicator":"No"},{"value":"Investigator discretion","valueDescription":"Investigator Discretion","ValueMeaning":{"publicId":"7715439","version":"1","preferredName":"Investigator Discretion","longName":"7715439","preferredDefinition":"An individual who conducts scientific research. In a clinical setting this individual actually conducts and/or supervises the clinical investigation and study-related procedures.  The investigator monitors the safety of the trial subjects and investigational staff (under whose immediate direction an agent is administered or dispensed to a subject).  The investigator collects and analyses data and study documents, and provides reports in compliance with applicable requirements.: The freedom or authority to act according to one's own judgment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Investigator","conceptCode":"C25936","definition":"An individual who conducts scientific research. In a clinical setting this individual actually conducts and/or supervises the clinical investigation and study-related procedures.  The investigator monitors the safety of the trial subjects and investigational staff (under whose immediate direction an agent is administered or dispensed to a subject).  The investigator collects and analyses data and study documents, and provides reports in compliance with applicable requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Discretion","conceptCode":"C180582","definition":"The freedom or authority to act according to one's own judgment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C596D2C8-8C22-7F58-E053-4EBD850AE477","latestVersionIndicator":"Yes","beginDate":"2021-06-25","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-06-25","modifiedBy":"ONEDATA","dateModified":"2022-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6F1DA11-6E43-1D9A-E053-4EBD850AC78E","beginDate":"2021-06-25","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-07-12","modifiedBy":"ONEDATA","dateModified":"2021-07-12","deletedIndicator":"No"},{"value":"Protocol recommended arm assignment","valueDescription":"Study Protocol Recommendation Protocol Treatment Arm Assignment","ValueMeaning":{"publicId":"7715440","version":"1","preferredName":"Study Protocol Recommendation Protocol Treatment Arm Assignment","longName":"7715440","preferredDefinition":"The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.: Advice telling someone what the best thing to do is.: A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: An allotting or an appointment to a particular person or use, or for a particular time or object.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Study Protocol","conceptCode":"C70817","definition":"The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Recommendation","conceptCode":"C25197","definition":"Advice telling someone what the best thing to do is.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assignment","conceptCode":"C25426","definition":"An allotting or an appointment to a particular person or use, or for a particular time or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C596D2C8-8C4C-7F58-E053-4EBD850AE477","latestVersionIndicator":"Yes","beginDate":"2021-06-25","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-06-25","modifiedBy":"ONEDATA","dateModified":"2021-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C596D2C8-8C67-7F58-E053-4EBD850AE477","beginDate":"2021-06-25","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-06-25","modifiedBy":"ONEDATA","dateModified":"2021-06-25","deletedIndicator":"No"},{"value":"Arm S: Induction Systemic Therapy previously received","valueDescription":"Protocol Treatment Arm Induction Systemic Therapy Previous Receive","ValueMeaning":{"publicId":"8013863","version":"1","preferredName":"Protocol Treatment Arm Induction Systemic Therapy Previous Receive","longName":"8013863","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: The act of bringing about something.: Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.: Occurring prior to something else.: To take, accept, or get something offered.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Induction","conceptCode":"C61367","definition":"The act of bringing about something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Previous","conceptCode":"C25627","definition":"Occurring prior to something else.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D67D17E6-94E4-404F-E053-4EBD850A625F","latestVersionIndicator":"Yes","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"ONEDATA","dateModified":"2022-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D67D17E6-94FF-404F-E053-4EBD850A625F","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"ONEDATA","dateModified":"2022-01-26","deletedIndicator":"No"},{"value":"Arm H: CAPOX + Nivolumab","valueDescription":"Protocol Treatment Arm CAPOX-Nivolumab Regimen","ValueMeaning":{"publicId":"8013864","version":"1","preferredName":"Protocol Treatment Arm CAPOX-Nivolumab Regimen","longName":"8013864","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A chemoimmunotherapy regimen consisting of capecitabine and oxaliplatin (CAPOX), plus nivolumab that can be used for the treatment of esophageal, esophagogastric junction and gastric cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"CAPOX-Nivolumab Regimen","conceptCode":"C185315","definition":"A chemoimmunotherapy regimen consisting of capecitabine and oxaliplatin (CAPOX), plus nivolumab that can be used for the treatment of esophageal, esophagogastric junction and gastric cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D67D17E6-950C-404F-E053-4EBD850A625F","latestVersionIndicator":"Yes","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"ONEDATA","dateModified":"2022-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D67D17E6-9527-404F-E053-4EBD850A625F","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"ONEDATA","dateModified":"2022-01-26","deletedIndicator":"No"},{"value":"Arm G: FOLFOX + Nivolumab","valueDescription":"Protocol Treatment Arm FOLFOX-Nivolumab Regimen","ValueMeaning":{"publicId":"8013865","version":"1","preferredName":"Protocol Treatment Arm FOLFOX-Nivolumab Regimen","longName":"8013865","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A chemoimmunotherapy regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus nivolumab that can be used for the treatment of esophageal, esophagogastric junction and gastric cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"FOLFOX-Nivolumab Regimen","conceptCode":"C185309","definition":"A chemoimmunotherapy regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus nivolumab that can be used for the treatment of esophageal, esophagogastric junction and gastric cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D67D17E6-9534-404F-E053-4EBD850A625F","latestVersionIndicator":"Yes","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"ONEDATA","dateModified":"2022-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D67D17E6-954F-404F-E053-4EBD850A625F","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"ONEDATA","dateModified":"2022-01-26","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":null,"ValueMeaning":{"publicId":"7590024","version":"1","preferredName":"Not Applicable","longName":"7590024","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCB96B6E-DDC3-6924-E053-4EBD850AEF18","latestVersionIndicator":"Yes","beginDate":"2021-03-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2021-03-04","modifiedBy":"KUMMEROA","dateModified":"2023-11-29","changeDescription":null,"administrativeNotes":"7/8/22 added alt name of NA for CCTG cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FBBEFBE0-1E88-16D7-E053-731AD00A677B","beginDate":"2023-05-15","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-05-15","modifiedBy":"FINCHAMB","dateModified":"2023-05-15","deletedIndicator":"No"},{"value":"Doublet","valueDescription":null,"ValueMeaning":{"publicId":"14598148","version":"1","preferredName":"Doublet","longName":"14598148v1.00","preferredDefinition":"Doublet","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09957A3B-02EE-6B02-E063-731AD00A88BF","latestVersionIndicator":"Yes","beginDate":"2023-11-07","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-11-07","modifiedBy":"FINCHAMB","dateModified":"2023-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"09957A3B-02F0-6B02-E063-731AD00A88BF","beginDate":"2023-11-07","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-11-07","modifiedBy":"FINCHAMB","dateModified":"2023-11-07","deletedIndicator":"No"},{"value":"Single-agent","valueDescription":null,"ValueMeaning":{"publicId":"14598149","version":"1","preferredName":"Single-agent","longName":"14598149v1.00","preferredDefinition":"Single-agent","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09957A3B-02EF-6B02-E063-731AD00A88BF","latestVersionIndicator":"Yes","beginDate":"2023-11-07","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-11-07","modifiedBy":"FINCHAMB","dateModified":"2023-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"09957A3B-02F1-6B02-E063-731AD00A88BF","beginDate":"2023-11-07","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-11-07","modifiedBy":"FINCHAMB","dateModified":"2023-11-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6906371E-11BA-4BF1-E053-F662850AF52D","latestVersionIndicator":"Yes","beginDate":"2018-04-04","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-04-04","modifiedBy":"FINCHAMB","dateModified":"2023-11-07","changeDescription":"Created for EA2165, 04/04/2018 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3852751","version":"1","longName":"Therapeutic","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"3314497","version":"1","longName":"Treatment","context":"ECOG-ACRIN"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Planned chemotherapy type","type":"Preferred Question Text","description":"Planned chemotherapy type","url":null,"context":"ECOG-ACRIN"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"93C7EEF8-17D3-43CF-E053-F662850A6C13","latestVersionIndicator":"Yes","beginDate":"2019-09-30","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-09-30","modifiedBy":"GARRIDOJ","dateModified":"2021-03-08","changeDescription":"Created for EA5181, 09/30/2019 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}